Federal Register / Vol. 83, No. 165 / Friday, August 24, 2018 / Notices 42919 

APPENDIX A—CERTIFIED HEALTH IT COMPARISON TOOLS IDENTIFIED THROUGH ONC MARKET RESEARCH

Comparison tool Company website 

4Med+ Marketplace .............................. www.4medapproved.com/wizard/marketplace. 

AmericanEHR ....................................... www.americanehr.com. 

Blackbook ............................................. www.blackbookrankings.com/healthcare. 

California Healthcare Foundation ......... www.chcf.org/publications/2007/10/ehr-selection-toolkit-for-community-health-centers. 

CHPL 4.0 .............................................. www.healthit.gov/chpl. 

Consumer Affairs .................................. www.consumeraffairs.com/emr-software. 

EHR Compare ...................................... www.ehrcompare.com. 

EHR in Practice .................................... www.ehrinpractice.com/ehr-product-comparison.html. 

Gartner ................................................. www.gartner.com. 

HealthRecord.US .................................. www.healthrecord.us. 

IDC Health Insights .............................. www.idc.com. 

KLAS .................................................... www.klasresearch.com. 

LeadingAge .......................................... www.leadingage.org/ehr/search.aspx. 

NCQA ................................................... www.ncqa.org/Programs/Recognition/practices/PatientCenteredMedicalHomePCMH/ 

PCMHPrevalidationProgram/VendorList.aspx. 

Software Advice ................................... www.softwareadvice.com. 

Software Insider ................................... www.ehr.softwareinsider.com. 

Technology Advice ............................... www.technologyadvice.com/medical/ehr-emr/smart-advisor. 

Texas Medical Association (TMA) ....... www.texmed.org/EHRTool. 

[FR Doc. 2018–18297 Filed 8–23–18; 8:45 am] 

BILLING CODE 4150–45–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The invention listed below is 

owned by an agency of the U.S. 

Government and is available for 

licensing to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

FOR FURTHER INFORMATION CONTACT: 

Vince Contreras, Ph.D., 240–669–2823; 

vince.contreras@nih.gov. Licensing 

information and copies of the U.S. 

patent application listed below may be 

obtained by communicating with the 

indicated licensing contact at the 

Technology Transfer and Intellectual 

Property Office, National Institute of 

Allergy and Infectious Diseases, 5601 

Fishers Lane, Rockville, MD, 20852; tel. 

301–496–2644. A signed Confidential 

Disclosure Agreement will be required 

to receive copies of unpublished patent 

applications. 

SUPPLEMENTARY INFORMATION: 

Technology description follows. 

Prefusion HPIV F Immunogens and 

Their Use 

Description of Technology: Human 

parainfluenza virus (hPIV) is an RNAbased paramyxovirus that causes 

respiratory infections in children and 

adults. There are four serotypes that can 

result in a myriad of diseases of the 

respiratory tract including croup, 

bronchitis, and pneumonia (Mao et al., 

2012). hPIV is a leading cause of 

respiratory tract infection and 

hospitalization among children under 5, 

only surpassed by the respiratory 

syncytial virus (RSV). Currently, there 

are limited treatment options and no 

approved vaccines. Recently, studies 

showed that a large proportion of 

neutralizing antibodies preferentially 

recognize exposed epitopes in the 

prefusion conformation of the RSV F 

protein, which together with other 

evidence suggests that creation of 

stabilized prefusion F protein 

immunogens might be a universal 

strategy to develop vaccine candidates 

for inducing protective immune 

responses in RSV and other related 

viruses, such as hPIV. 

Researchers at the Vaccine Research 

Center (VRC) of the National Institute of 

Allergy and Infectious Diseases created 

immunogenic PIV fusion (F) 

glycoproteins for types 1,2,3 and 4 

(hPIV1, hPIV2, hPIV3 and hPIV4) that 

have been modified to stabilize the 

prefusion conformation. 

These stabilized prefusion F 

immunogens, especially hPIV3, induced 

high titer neutralizing responses in mice 

and rhesus macaques, and should thus 

serve as promising candidates for the 

prevention of PIV infection in humans. 

This technology is available for 

licensing for commercial development 

in accordance with 35 U.S.C. 209 and 37 

CFR part 404. 

Potential Commercial Applications: 

• hPIV vaccines for people of all ages; 

• Specific focus on the elderly and 

young children. 

Competitive Advantages: 

• Use as a multivalent hPIV vaccine; 

• Use in combination with influenza 

or RSV vaccine compositions; 

• hPIV3 neutralizing titers induced in 

both mice and rhesus macaques were 

substantially higher than the highest 

PIV3 neutralizing titers observed in a 

cohort of over 100 humans. 

Development Stage: 

• In vivo testing (primates and mice). 

Inventors: Peter Kwong (NIAID), GwoYu Chuang (NIAID), Kai Xu 

(NIAID),Tongqing Zhou (NIAID), 

Yaroslav Tsybovsky (Leidos Biomedical 

Research, Inc), Aliaksandr Druz 

(NIAID), Antonio Lanzavecchia 

(Institute for Research in Biomedicine), 

Davide Corti (Institute for Research in 

Biomedicine), Guillaume BE StewartJones (NIAID), Baoshan Zhang (NIAID), 

Yongping Yang (NIAID), Paul Thomas 

(NIAID), John Mascola (NIAID), Li Ou 

(NIAID), Wing-pui Kong (NIAID). 

Intellectual Property: HHS Reference 

Number E–215–2016 includes U.S. 

Provisional Patent Application Number 

62/412,699 filed 10/25/2016 and PCT 

Application Number PCT/US2017/ 

058322 filed 10/25/2017 (pending). 

Related Intellectual Property: HHS 

Reference Number: E–064–2016. 

Licensing Contact: Vince Contreras, 

Ph.D., 240–669–2823; vince.contreras@

nih.gov. 


daltland on DSKBBV9HB2PROD with NOTICES
42920 Federal Register / Vol. 83, No. 165 / Friday, August 24, 2018 / Notices 

Dated: August 10, 2018. 

Suzanne M. Frisbie, 

Deputy Director, Technology Transfer and 

Intellectual Property Office, National Institute 

of Allergy and Infectious Diseases. 

[FR Doc. 2018–18397 Filed 8–23–18; 8:45 am] 

BILLING CODE 4140–01–P 

ADVISORY COUNCIL ON HISTORIC 

PRESERVATION 

Notice of Issuance of Program 

Comment To Exempt Consideration of 

Effects to Rail Properties Within Rail 

Rights-of-Way 

AGENCY: Advisory Council on Historic 

Preservation. 

ACTION: Program Comment issued to 

exempt consideration of effects to rail 

properties within rail rights-of-way. 

SUMMARY: The Advisory Council on 

Historic Preservation (‘‘ACHP’’) issued a 

Program Comment to exempt 

consideration of effects to rail properties 

within rail rights-of-way at the request 

of the U.S. Department of 

Transportation to accelerate the review 

of these undertakings under Section 106 

of the National Historic Preservation Act 

and to meet the requirement of Section 

11504 of the Fixing America’s Surface 

Transportation Act. The Program 

Comment can be used by any federal 

agency with responsibility to consider 

the effects of undertakings within rail 

rights-of-way. Federal agencies using 

the Program Comment may fulfill their 

Section 106 responsibilities for the 

relevant undertakings by implementing 

the terms of this comment, which 

include identifying those activities that 

meet the conditions in Appendix A and 

opting into the process to identify 

excluded historic rail properties and 

seek further streamlining of the review 

process under the property-based 

approach. 

DATES: The Program Comment was 

issued by the ACHP on August 17, 2018. 

ADDRESSES: Address all questions 

concerning the Program Comment to 

Kelly Y. Fanizzo, Office of General 

Counsel, Advisory Council on Historic 

Preservation, 401 F Street NW, Suite 

308, Washington, DC 20001–2637. You 

may submit questions through 

electronic mail to: kfanizzo@achp.gov. 

FOR FURTHER INFORMATION CONTACT: 

Kelly Y. Fanizzo, (202) 517–0193, 

kfanizzo@achp.gov. 

SUPPLEMENTARY INFORMATION: Section 

106 of the National Historic 

Preservation Act (‘‘NHPA’’), as 

amended, 54 U.S.C. 306108 (‘‘Section 

106’’), requires federal agencies to take 

into account the effects of undertakings 

they carry out, license, permit, or fund 

to historic properties and provide the 

Advisory Council on Historic 

Preservation (‘‘ACHP’’) a reasonable 

opportunity to comment with regard to 

such undertakings. The ACHP has 

issued the regulations that set forth the 

process through which federal agencies 

comply with these responsibilities. 

Those regulations are codified under 36 

CFR part 800 (‘‘Section 106 

regulations’’). 

Under Section 800.14(e) of those 

regulations, federal agencies can request 

the ACHP to issue a ‘‘Program 

Comment’’ on a particular category of 

undertakings in lieu of conducting 

reviews for each individual undertaking 

in the category. An agency can meet its 

Section 106 responsibilities with regard 

to the effects of those undertakings by 

implementing an applicable Program 

Comment that has been issued by the 

ACHP. 

I. Background 

At the request of the U.S. Department 

of Transportation (‘‘USDOT’’), the 

ACHP has issued a Program Comment 

that provides new efficiencies in the 

Section 106 review for undertakings 

with the potential to affect historic rail 

properties within railroad and rail 

transit rights-of-way (‘‘rail ROW’’). 

Section 11504 of the Fixing America’s 

Surface Transportation Act (‘‘FAST 

Act’’) (49 U.S.C. 24202), enacted on 

December 4, 2015, mandated the 

development of a Section 106 

exemption for ‘‘railroad rights-of-way.’’ 

The FAST Act required that ‘‘the 

Secretary [of the USDOT] shall submit 

a proposed exemption of railroad rightsof-way from the review under section 

306108 of title 54 to the [ACHP] for 

consideration, consistent with the 

exemption for interstate highways 

approved on March 10, 2005 (70 FR 

11928).’’ The FAST Act continued that, 

‘‘Not later than 180 days after the date 

on which the Secretary submits the 

proposed exemption . . . to the 

Council, the Council shall issue a final 

exemption of railroad rights-of-way 

from review under chapter 3061 of title 

54 consistent with the exemption for 

interstate highways approved on March 

10, 2005 (70 FR 11928).’’ While the 

Section 106 regulations provide the 

process and criteria for development of 

program alternatives, the FAST Act 

modified the timeframe and directed 

agency actions. 

The ACHP worked closely with the 

Federal Railroad Administration 

(‘‘FRA’’), the Federal Transit 

Administration (‘‘FTA’’), the Federal 

Highway Administration (‘‘FHWA’’), 

and the Office of Policy Development, 

Strategic Planning, and Performance 

within the Office of the Secretary, 

USDOT (‘‘OST–P’’); representatives 

from the railroad and rail transit 

industries; and historic preservation 

stakeholders to develop the final 

Section 106 program alternative for rail 

ROW. The ACHP communicated 

extensively with the staff of the Senate 

Committee on Commerce, Science, and 

Transportation (‘‘Senate Committee’’) as 

well in developing this program 

alternative. The ACHP recommended 

incorporating the originally proposed 

exemption within a Program Comment 

to better achieve the intent and purpose 

of the FAST Act and meet the needs of 

the various stakeholders. 

The Program Comment is the product 

of consultation and careful review. The 

USDOT and FRA conducted outreach 

on the preliminary exemption concept 

and early drafts prior to submitting a 

formal request to the ACHP in July 

2017. The ACHP in turn published the 

draft Program Comment in the Federal 

Register (82 FR 54390, November 17, 

2017), and hosted additional meetings 

with industry and preservation 

representatives in 2018. Recognizing the 

complexity of the issues to be addressed 

and wanting to ensure the final product 

met the statutory requirement of the 

FAST Act to be consistent with the 

interstate highway exemption, the staff 

for the Senate Committee extended the 

deadline for the final issuance of the 

Program Comment. The final Program 

Comment takes into account the many 

significant comments and questions 

raised by various stakeholders over the 

course of its development and 

represents the collective work of the 

ACHP, USDOT (inclusive of FRA, FTA, 

FHWA, and OST–P), and the Senate 

Committee staff to ensure that it meets 

the FAST Act requirement. 

The Program Comment is comprised 

of two major parts: (1) An activity-based 

approach, and (2) a property-based 

approach. The activity-based approach 

provides a list of activities in Appendix 

A for which, when the specific 

conditions are met, no further Section 

106 review is required. Based on the 

past experience of USDOT Operating 

Administrations (‘‘USDOT OAs’’), 

undertakings limited to the activities 

specified in Appendix A have typically 

resulted in effects to historic properties 

that are either minimal or not adverse. 

The property-based approach 

establishes a process whereby project 

sponsors can opt to work with the 

relevant USDOT OA and stakeholders to 

develop a list of excluded historic rail 

properties that would remain subject to 

Section 106 review, and exempt from 


daltland on DSKBBV9HB2PROD with NOTICES